Inter Milan produced another rousing comeback to beat Udinese 5-3 at San Siro and continue their perfect start to the new Serie A campaign.
Udinese had taken a shock 2-0 lead through James Abankwah's early header and then a close-range strike from Jurgen Ekkelenkamp.
The Nerazzurri - who had come from 2-0 down to beat Napoli late on in their last Serie A game - fought back as Carlos Augusto drilled in a long-range effort and Nicolo Barella equalized before half-time.
Marcus Thuram's sweeping finish completed the turnaround in the 57th minute, before England defender John Stones - making a first start since his free transfer move from Manchester City - limped off having pulled up after chasing an Udinese breakaway.
Pio Esposito and substitute Ange-Yoan Bonny then wrapped things up, with Idrissa Gueye scoring a late consolation for the visitors, as Cristian Chivu's men kept pace with leaders Roma on a 100% record from four league games.

#Milan

For the second Serie A game in a row, Inter came back from 2-0 down to win, this time crushing Udinese 5-3 in a chaotic encounter at San Siro.
The Nerazzurri had a perfect start in Serie A thanks to a comeback from 2-0 down to beat Napoli 3-2, but lost their Champions League opener 2-1 to Real Madrid this week following some costly individual errors.
Cristian Chivu rotated, giving John Stones his first start, but resting Lautaro Martinez, Yann Bisseck and Hakan Calhanoglu, along with not fully fit Federico Dimarco and injured Djed Spence. The Friulani had an injury crisis, missing Oumar Solet, Nicolò Zaniolo, Juan Arizala, Matteo Palma and Jakub Piotrowski, the Poland international undergoing surgery today to correct a benign cardiac arrhythmia.
See how it all unfolded on the Liveblog.
MILAN, ITALY – SEPTEMBER 14: James Abankwah of Udinese Calcio celebrates scoring his team's first goal during the Serie A match between FC Internazionale and Udinese Calcio at Stadio Giuseppe Meazza on September 14, 2026 in Milan, Italy. (Photo by Claudio Villa/Getty Images)

#serie #udinese #italy #start

Sept 14 (Reuters) - Hollywood designer Bob Mackie, known for making stars such as Cher and ‌Elton John sparkle, died on Monday at ‌87, according to a post on his official Instagram account.
His career spanned five decades and included designing a Barbie doll clothes collection.
Born in 1939 into a middle-class family in Monterey Park, California, he was nominated for ‌more than 30 ⁠Emmys, winning nine. He received Academy Award nominations for costumes worn in ⁠the films "Lady Sings the Blues," "Funny Lady," and "Pennies From Heaven."
"His genius and extraordinary designs will live on forever, continuing to bring beauty into this world," his ‌team said in an Instagram post. His cause of death was not stated.
Mackie was known for sequins, rhinestones and glitter, but also humor. The highlight of his 11-year run for The Carol ‌Burnett Show was the "curtain dress" worn by Burnett in a sketch parodying 1939 film classic "Gone with the Wind." ‌The costume, now in the collection of the Smithsonian's American History Museum, included a brass curtain rod balanced on Burnett's shoulders and a bit ‌of valance worn as a hat.

#post

Bob Mackie, the dress designer to the stars known as the "Rajah of Rhinestones" thanks to his legendarily glittery, flashy designs for the likes of Cher, Elton John, Bette Midler, Carol Burnett and Barbra Streisand has died at 87.
A statement on Mackie's Instagram page on Monday morning (Sept. 14) announced the news, reading, "It is with a heavy heart that we share the news that Mr. Bob Mackie passed away today. He lived his 87 years to the fullest, fulfilling his dream of being a Fashion and Costume Designer, which is all he ever wanted to do. His genius and extraordinary designs will live on forever, continuing to bring beauty into this world."
More from Billboard
Inspired By U2, Oprah Winfrey Bringing Immersive, Star-Studded 'AHA' Experience to Las Vegas' Sphere
Pop Stars Paying Homage to Bob Mackie: See the Classic Looks Then and Now

#stars #cher

The fashion and costume designer Bob Mackie, whose glittering creations have been worn by Cher, Dolly Parton, Tina Turner and Miley Cyrus, has died at age 87, according to his social accounts.
"It is with a heavy heart that we share the news that Mr. Bob Mackie passed away today. He lived his 87 years to the fullest, fulfilling his dream of being a Fashion and Costume Designer, which is all he ever wanted to do," read a post on his Instagram account. "His genius and extraordinary designs will live on forever, continuing to bring beauty into this world."
Mackie became known for his glamorous designs after collaborating with Cher, dressing her on television and on tour. He also served as the costume designer for "The Carol Burnett Show," responsible for Burnett's entire wardrobe. Nicknamed the Sultan of Sequins, the Rajah of Rhinestones and the Guru of Glitter, Mackie's ostentatious, flattering looks became instantly recognizable over the course of his career. His popularity continued into the modern day, with his archive coveted by a new generation of stars.
For his stage and screen work, Mackie has been awarded nine Emmys, an induction into the Television Academy Hall of Fame and three Academy Award nominations. In 1999, he received a retrospective at the Museum at FIT. More recently, he won a Tony Award for the musical "The Cher Show" and a lifetime achievement award by the Council of Fashion Designers of America.
Fern Mallis, former executive director of CFDA and founder of New York Fashion Week, credited him with many of the red carpet trends we continue to see today.

#costume #show #academy #television

The Washington Nationals bullpen blowing games is nothing new and we saw that today. However, the offense bailing out the bullpen and fighting back in the late innings was something different. That fight late in the game helped the Nats get their second walk off win of the season and win the series against the Angels,
As we have discussed, CJ Abrams has really been struggling lately. However, this series has seen a much more lively version of Abrams. While the Angels are not a good team, you cannot solely attribute this improvement to just seeing bad pitching. Walbert Urena was averaging over 99 MPH, but Abrams was still able to get the Nats on the board with an RBI double in the 1st.
cj x abi run collab pic.twitter.com/eWgugX0ZfM
These last couple of weeks are very important for the Nats shortstop/second baseman. His OPS is still a ways off what it was a couple months ago. However, if he can stabilize these last couple of weeks, he can end the season on a positive note. There are still plenty of milestones for CJ to reach. He is one stolen base away from a 30-30 season and 4 RBI's away from 100.
His 29th stolen base was perhaps his most important of the season. In the bottom of the 10th inning, the Nats had runners on first and second with 1 out. Abrams noticed that the pitcher was not paying enough attention to him and took off. He swiped third base without a throw. That stolen base ended up winning the Nats the game.

#season #base #still

Federico Dimarco is closing in on a return to Inter's matchday squad for Monday's clash with Udinese at San Siro, with Cristian Chivu weighing several further changes to his starting XI following the Champions League trip to Real Madrid.
According to TuttoMercatoWeb, the Nerazzurri boss is treating the fixture as more than a simple fatigue-management exercise. The report frames it as evidence of a genuine rotation policy, made possible by the depth Inter built during the summer transfer window.
Dimarco has been managing a knee sprain picked up in recent days, and while the issue kept him sidelined, he has now completed part of the latest training session alongside his teammates before continuing with individual work. His call-up against Udinese appears probable, though Chivu still must decide whether to throw him straight back into the action or ease him in gradually, as detailed in SempreInter's recent coverage of Dimarco's situation.
Djed Spence remains further off the pace. The wing-back continues his individual work on the pitch but is edging closer to a full return to group training.
John Stones could be handed his first start of the season after a string of promising cameos, including his second-half introduction in Madrid. A Stones start would mark the fourth different defensive trio Chivu has fielded in five matches this season.

#stones #individual

Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement.
The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing Rate, plus 6.15%, payable monthly. The formula sets a 9.15% minimum. Applying that floor to the initial borrowing produces approximately $6.9 million of article-calculated annual interest before commitment, administrative, undrawn-amount, and facility fees.
The financing arrives as Intellia Therapeutics, Inc. (NASDAQ:NTLA) prepares for a potential U.S. launch of lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema. Intellia Therapeutics, Inc. (NASDAQ:NTLA) held $628.4 million of cash, cash equivalents, and marketable securities as of June 30, but reported a $106.6 million second-quarter net loss.
The staged structure gives Intellia Therapeutics, Inc. (NASDAQ:NTLA) capital without issuing equity at closing and avoids drawing the full amount before milestones that could support additional debt.
A second $75 million tranche becomes available at the option of Intellia Therapeutics, Inc. (NASDAQ:NTLA) if the FDA approves the biologics license application for lonvo-z before a specified date. Three further $40 million tranches depend on lonvo-z revenue targets, while another $30 million requires an equity-fundraising milestone. This links most committed borrowing capacity to regulatory and commercial progress.

#million #therapeutics #ntla #lonvo

Saturday isn't just another game for the Oregon Ducks. A couple of milestones are attached as the boys in green and white travel down to Stillwater to face the Oklahoma State Cowboys.
For starters, Dan Lanning has something on the line this week against the Cowboys. With a victory, the Ducks' 40-year-old head coach will celebrate his 50th career win at Oregon, which would put him in an elite club in program history.
That milestone may not come with a banner or a trophy, but it puts him in rarefied air in Eugene; the last Oregon coach to cross 50 wins was Mike Bellotti, back in 2001, his seventh year at the helm.
Since Bellotti, coaches like Chip Kelly, Mark Helfrich, Willie Taggart, and Mario Cristobal have all fallen short of the mark that Lanning is about to hit in his fifth season. In Oregon history, only three other coaches have crossed the 50-win mark: Bellotti, Rich Brooks, and Len Casanova.
Chip Kelly notably had 46 wins in four seasons as the Ducks' head coach.

#chip

Investors love to check automakers' quarterly (or otherwise) delivery figures, especially when it comes to young electric vehicle (EV) makers that are surviving amid low volume and scale. Rivian's (NASDAQ: RIVN) R2 has been long-hyped, and on June 9, 2026, customers finally began receiving their prized ride. However, while Wall Street ****** ysts obsess over delivery charts and the smallest gains or losses, savvy investors know the R2 is about much more than increasing deliveries and revenue for the young EV maker. Here is one big development that's often forgotten.
One of Rivian's underappreciated strengths is its ability to bring in investment from larger companies that see value in Rivian's software technology or vehicles as a service. In this case, Rivian's mass-market R2 was a solid choice for Uber Technologies (NYSE: UBER) to add to its numerous investments for robotaxi joint ventures. Uber will invest up to $1.25 billion in Rivian through 2031, after it meets certain conditions and milestones, and the statement from Uber CEO Dara Khosrowshahi emphasizes Rivian's growing value with its vertical integration.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
"We're big believers in Rivian's approach -- designing the vehicle, compute platform, and software stack together, while maintaining end-to-end control of scaled manufacturing and supply in the U.S.," Khosrowshahi said in a press release.
Uber and Rivian expect to deploy 10,000 fully autonomous R2 robotaxis during their joint venture's first phase. San Francisco and Miami are circled in red to host the initial R2 robotaxi deployments in 2028, with the target of entering 25 additional cities by 2031. If all goes well for the joint venture, there's an option for the companies to negotiate the purchase of up to 40,000 additional R2 vehicles beginning in 2030.

#uber #delivery #young

Dame Helen Mirren attended the MobLand Season Two world premiere, held at Odeon Luxe Leicester Square in London this evening, ahead of the new season's Paramount+ debut on September 18.
Neil Mockford/Getty Images
The actress, who plays Maeve Harrigan, head of the Harrigan crime family, brought her usual dazzle and charm to the red carpet wearing the Jenny Packham Dulcet sequinned gown.
Jenny Packham, a long-time favourite of the Princess of Wales, has built her reputation on eveningwear that celebrates embellishment, so perhaps it was inevitable that the sequins wouldn't be the end of the story. Rhinestones across the shoulders created an almost armour-like effect. It could have felt excessive, yet on Helen it only added to the sense of occasion.
A silver-metal Tyler Ellis Perry clutch and an updo, which showed off her Anabela Chan earrings, completed her look.

#mirren

Anna Wintour allegedly rejected Dolly Parton for a Vogue cover several times because of the country icon's signature style. A new insider report claims Parton's rhinestones and towering wigs did not fit Wintour's vision for the magazine. The claim has resurfaced shortly after Parton's death, putting another spotlight on her unmistakable fashion legacy. It also raises questions about why the style icon never landed the coveted cover.
According to Rob Shuter's Naughty But Nice report, Parton was pitched for an American Vogue cover at least four times. However, the report claims Wintour repeatedly passed on the idea.
One insider alleged that Wintour considered Parton "too country, too camp and too tacky for Vogue." The source claimed Wintour focused on her exaggerated glamour rather than her broader cultural influence.
Parton never toned down that look. Instead, big hair, sparkling outfits and sky-high heels became central to her image. Her distinctive style eventually became as recognizable as many of her songs.
Still, Vogue did feature Parton inside the magazine. The publication recently revisited its 1994 profile, "Good Golly Miss Dolly," following her death. Charles Gandee wrote the piece, while Herb Ritts photographed Parton for the January 1994 issue.

#cover #report #times

Dua Lipa and Callum Turner share a love of traveling
The couple, who married in May 2026, have vacationed across the world
The "One Kiss" singer frequently shares sweet pictures of her and her husband globetrotting
If there's one thing Dua Lipa and Callum Turner love to do, it's travel together!
The "Houdini" singer and the One Night Only actor have celebrated major milestones and embarked upon several adventures together across the world ever since they started dating in January 2024. Lipa even made their relationship Instagram official by posting a picture of them hanging out at a festival in England.

#callum #turner #singer

Taylor Swift brought some serious sparkle to her latest date night with Travis Kelce. The singer stepped out in New York City on September 6 alongside her husband, delivering an elegant evening look packed with luxe details. While her striped high-slit dress made a statement of its own, Swift's jewelry collection, including gorgeous earrings, took the look to an entirely different price bracket.
Taylor Swift accessorized with Mindi Mond's Imperial Citrine & Diamond Drop Earrings, which retail for a whopping $19,000. The striking earrings feature enormous cushion-cut citrine stones suspended beneath glittering round diamonds, bringing a rich golden-yellow pop of color to her look. According to the product listing, the earrings feature a total citrine weight of 31 carats alongside 1.20 carats of diamonds.
Swift let the statement jewels peek through her softly styled brown waves, which she wore down with her signature bangs. The warm tone of the citrine also complemented the earthy palette of her striped Stella silk blend McCartney halter-neck maxi dress without competing with it. Priced at $2,800, the dress made for a perfect date night look. It featured an asymmetric neckline and a high slit that flashed her leg as she walked.
In addition, the $19K earrings weren't the only major jewels involved. Swift also wore an Elizabeth Taylor Darlene De Sedle 22-karat gold, opal, and diamond bracelet and ring set. Most notably, her custom Kindred Lubeck of Artifex Fine Jewelry diamond engagement ring and wedding band were also on display.
She completed the outfit with metallic Twist 95 Sandals by Aquazzura and a Frayme Scale-Embossed Bucket Bag by Stella McCartney. These luxury accessories also came with a costly price tag. She walked hand-in-hand with her husband, who wore brown pants and a soft mint-green shirt.

#earrings #dress

Real Madrid host Inter Milan in the opening game of the Champions League's Group Stage. Los Blancos are coming off a disappointing loss against Betis, so bouncing back tonight would improve the team's confidence and momentum.
Real Madrid predicted XI: Courtois; Dumfries, Konaté, Huijsen, Cucurella; Valverde, Bellingham; Brahim, Diomande, Vinicius; Mbappé.
Inter Milan predicted XI: Martínez; Bisseck, Stones, Bastoni; Luis Henrique, Barella, Calhanoglu, Jones, Carlos Ausgusto; Lautaro, Thuram.
Mourinho will have to rebuild his midfield line given that Güler, Camavinga and Bernardo Silva are all out. Bellingham will likely be deployed alongside Valverde in the double pivot, with Brahim and Diomande playing in the attacking line.
HOW TO WATCH, STREAM CHAMPIONS LEAGUE

#madrid #brahim #diomande

On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the pharmacy counter: ICOTYDE, an oral psoriasis treatment, and rusfertide, an injectable now awaiting an FDA decision. Cash and marketable securities climbed to $849.5 million. Here's what's fueling the optimism, and what could complicate it.
The quarter marked the first full three months of commercial sales for ICOTYDE, which won FDA approval on March 18 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg. That approval triggered a $50 million milestone payment and made ICOTYDE, according to the company, the first and only FDA-approved targeted oral peptide for the condition. Protagonist can still collect up to $580 million more in milestones from partner Johnson & Johnson, plus royalties that average around 7.25 percent at $4 billion in annual sales.
Rusfertide carries even more weight. Its new drug application sits under Priority Review with a PDUFA goal date in August, backed by Breakthrough Therapy, Orphan Drug, and Fast Track designations for polycythemia vera. Partner Takeda already paid Protagonist $200 million on an opt-out election in April, with another $200 million and a $75 million approval milestone still due, on top of royalties that can reach 29 percent of sales above $1.5 billion. Behind both drugs, PN-881, an oral IL-17 antagonist, is heading into a Phase 2b psoriasis program in early 2027 after Phase 1 data showed drug levels beating their pharmacokinetic targets, and a Phase 1 study just began for PN-477sc, an injectable obesity peptide.
Look closer at that $213.5 million in license and collaboration revenue, and $192.4 million of it traces to the proportional recognition of Takeda's initial opt-out payment, not repeatable product sales. A year earlier, the same line item was just $5.5 million, so the growth reflects a single deal event more than an operating business scaling up. And that opt-out itself cuts both ways: Protagonist gave up its right to develop and commercialize rusfertide on its own, trading full ownership for royalties and milestones that depend on Takeda's execution rather than Protagonist's.
Spending is also set to climb. Management expects research and development costs to increase significantly in the second half of 2026 versus the first half, driven by the new PN-881 Phase 2b program, manufacturing investments, and added headcount. General and administrative costs are rising too, largely on stock-based compensation. And rusfertide's fate still hinges on an FDA decision that hasn't happened yet, priority review or not.

#protagonist

Music legend Dolly Parton spent decades as one of country music's most beloved icons, but a new report claims that image never won over longtime Vogue editor Anna Wintour, who reportedly turned her away from the magazine's cover multiple times. Parton, 80, died on August 25 in Nashville following a brief battle with cancer.
In the Saturday, September 5 edition of journalist Rob Shuter's Naughty But Nice Substack, sources claimed Parton was pitched for the cover of American Vogue at least four times during Wintour's decades at the magazine and was repeatedly turned down.
Stacie Huckeba/Butterfly Records LLC
"Anna thought Dolly was too country, too camp and too tacky for Vogue," an insider told Naughty But Nice. "She looked at Dolly and saw rhinestones. The rest of America saw an icon. Anna completely missed it."
Shuter, who previously worked as a publicist, also wrote that he witnessed Wintour's approach to celebrity fashion firsthand. According to his account, Jessica Simpson, Alicia Keys and Jennifer Lopez also faced resistance before gaining greater acceptance within the fashion world.

#dolly #naughty #decades #turned

Inter completed an extraordinary comeback from 2-0 down to beat Napoli 3-2 with a Lautaro Martinez double and Marcus Thuram, sealing a true thriller at San Siro.
The top two in each of the last two seasons faced off, though the Nerazzurri had started stronger with victories over Monza and Cagliari. Marcus Thuram was still not fully fit and Djed Spence working his way back from injury, with John Stones and Hakan Calhanoglu rested ahead of the Champions League trip to Real Madrid.
Max Allegri had a rough week, losing at home to Como, then Scott McTominay and Giovane both required surgery, with Alessandro Buongiorno and Luca Marianucci already long-term absentees. Antonio Vergara was preferred to Kevin De Bruyne due to match fitness.
Napoli were unbeaten against Inter since the Supercoppa Italiana Final in January 2024, managing one win and four draws going into this test.
See how it all unfolded on the Liveblog.

#marcus

Dennis Quaid reflected on his son Jack Quaid's 2026 wedding, comparing it to dropping him off at college 16 years ago
Jack married Claudia Doumit, his costar on The Boys, in April
"It just, it really gets emotional," Dennis told PEOPLE exclusively
Dennis Quaid is feeling "very emotional" about his kids' life milestones.
Speaking exclusively with PEOPLE at the Nashville screening of documentary Water Wars on Wednesday, Sept. 2, the 72-year-old actor discussed his son Jack Quaid's recent wedding after opening up about dropping his 18-year-old twins, Thomas and Zoe, off at college.

#college #exclusively

An auction of the retail empire formerly owned by the Barclay family is set to be shelved after bidders failed to meet the £2bn asking price.
Very Group, the online retailer that also owns the Littlewoods brand, was bought by US private equity firm Carlyle for a nominal £1 sum last year and subsequently put up for sale.
But plans to sell the company now appear to be in jeopardy after none of the potential suitors, which included Chinese online giant JD.com, came up with offers large enough to meet Carlyle's demands, Sky News reported.
Carlyle, which had been Very's main creditor, seized control of Very in November following the collapse of the Barclay empire amid a dispute with Lloyds Banking Group about unpaid debts.
In addition to JD.com, possible bidders are said to have included investment firm Elliott, which owns Waterstones, and plus-size online retailer N Brown, which owns the Jacamo and Simply Be brands.

#owns #group #bidders #meet

Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc. have finalised an exclusive distribution and reseller agreement covering Virotek's ophthalmology genomic testing and screening programme in the United States.
Under the agreement, which took effect on September 4, 2026, Kala will serve as the sole U.S. distributor of the programme and will have the right to market, promote, distribute and resell Virotek's ophthalmology genetic testing services.
The agreement has an initial one-year term, with continued exclusivity dependent on Kala achieving agreed commercial milestones. It follows a non-binding letter of intent announced on September 1, 2026.
Virotek will remain responsible for the programme's infrastructure, supply of testing kits, specimen processing and clinical reporting. The company will also provide training and supporting materials to Kala's channel partners.
The companies have agreed to a profit-sharing arrangement that will take effect after Virotek recovers its programme costs. No additional financial terms were disclosed.

#programme

Bitcoin was trading at $77,121 on Thursday, having clawed back much of its summer losses in a sharp August rally.
The cryptocurrency gained roughly 24% during August alone, rising from around $62,600 at the start of the month to a peak of $80,797 on August 25.
That rebound has reshaped betting on Polymarket, the prediction market platform, where traders wager on which price milestones Bitcoin will hit before the end of 2026.
The market, which has attracted $62.1 million in trading volume since launching in November 2025, currently prices a rise to $90,000 at 44%.
A move to $100,000 is priced at 22%, while $110,000 sits at just 13%. On the downside, traders **** ign an 87% probability to Bitcoin falling below $55,000 again before the year is out, reflecting the scars of a volatile summer.

#summer

Gem Diamonds Limited (LSE:GEMD, OTC:GMDMF) shares saw a significant upward movement on Thursday following the release of its half-year results and a firm 'buy' reiteration from Panmure Liberum.
The shares traded up 70% to 11p as the broker held its 'buy' stance and 13p target price, digesting the miner's improved financial and operational footprint.
At the heart of the recovery is a 32% revenue increase to $59.7 million, driven by higher prices for Letšeng's large stones and strict cost-control measures.
That operational momentum, alongside extended royalty relief, propelled underlying earnings to $8.6 million, reversing a steep $2.6 million deficit from the same period last year.
Crucially, these cost-saving measures have strengthened the balance sheet, elevating cash reserves to $20.2 million and slashing net debt down to a mere $0.5 million.

#year #gmdmf

Former ****** nal and Manchester City fullback Bacary Sagna believes Inter Milan are "the perfect club" for England stars John Stones, Djed Spence and Curtis Jones.
Sagna argued that Inter Milan is the club in the Serie A that most resembles a Premier League club in terms of how they play.
Furthermore, Sagna, revealed that he is an Inter Milan and was close to joining the club. However the move never materialized and Sagna suggested this was a what-if moment in his career.
The former France international also praised Inter Milan's now former Sporting Director Piero Ausilio, who recently departed the club after 28 years.
Subsequently, Sagna backed Djed Spence to not only succeed at Inter Milan and the Serie A, but also deemed the England star as being better balanced than Denzel Dumfries who joined

#Inter #former

On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven's lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven's Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines up with an August 10, 2026 earnings report that showed Biohaven still losing well over $100 million a quarter, and the gap between those two dates explains a lot about why this deal happened now.
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no ******* ration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves' disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Biohaven is giving up full ownership of an ******* et it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim's future revenue before Biohaven sees a dollar of profit from it.

#ro

Fervo Energy (NASDAQ:FRVO), an enhanced geothermal power developer and independent power producer, closed at $19.75, up 28.41%. Pre-market, the company said it signed a 396-megawatt power purchase agreement with Alphabet's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google, and investors are watching next quarter's earnings and project milestones. Trading volume reached 35.0M shares, coming in about 851% above its three-month average of 3.7M shares. Fervo Energy IPO'd in 2026 and has fallen 46% since going public.
S&P 500 (SNPINDEX:^GSPC) closed at 7,633, down 0.70%, while the Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 26,100, down 1.03%. Among utility-scale geothermal power generation and geothermal technology peers, Ormat Technologies (NYSE:ORA) closed at $107.33, up 5.23%, and NextEra Energy (NYSE:NEE) closed at $82.91, up 0.69%, highlighting stronger interest in clean-power names tied to data-center demand.
Fervo Energy shares soared 28% after announcing a major 396-MW purchase agreement with Google, providing visibility into potential revenue for years to come from a top-tier customer. Google will also have the option to expand the deal by 600 MW, bringing it to nearly 1 GW in 2030.
Overall, the deal seems like a natural pairing. Fervo can begin selling power to Google in 2028 from its Cape Station project in Utah, while the company tries to build an artificial intelligence data center in the state. Though Google still has to jump through all the regulatory hurdles to build a data center there, Fervo's 24/7 carbon-free, thermal energy would be an ideal solution for the tech behemoth.
That said, Fervo's projects are still in progress, and Google's rapid data center build-out could decelerate due to any type of AI slowdown, so investors need to note that volatility is unavoidable in this virtually pre-revenue stock, especially as it will be under pressure to supply the amount of power needed in just a few years.

#NASDAQ

On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma's second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company that makes its living buying pieces of other companies' drugs, the timing says a lot about how it weighs risk against reward before a regulatory verdict even lands.
Royalty Pharma's business depends on picking the right moment to buy into a drug's future, and this deal fits that pattern. Under the agreement, $50 million changes hands at closing and the remaining $50 million arrives on the first anniversary, in exchange for a 1% royalty on rusfertide's global sales plus any regulatory and commercial milestones. Rusfertide, a once-weekly self-injected therapy that mimics the hormone hepcidin to control iron levels in polycythemia vera patients, already has an FDA goal date set for the third quarter of 2026, with Takeda lined up to handle commercialization worldwide. That is a near-term catalyst most royalty purchases do not carry.
The broader portfolio backs up the confidence. Royalty Receipts grew 14% to $768 million in the second quarter of 2026, lifted by Tremfya, Voranigo, Imdelltra and Evrysdi, and the company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3.4 billion to $3.5 billion, the second increase this year. Capital deployment has already topped $1 billion in 2026, including a July 2026 royalty purchase tied to AstraZeneca's cliramitug, pushing the development-stage pipeline to 19 potential therapies. Even after repaying a $380 million term loan in July 2026, Royalty Pharma still paid a quarterly dividend of $0.235 per share and bought back $45 million of stock in the second quarter alone.
Not every royalty ages well, and Royalty Pharma's own numbers show it. Promacta royalties fell 75% in the second quarter of 2026 to just $8 million as US generic competition took hold, and Imbruvica payments slipped 16% to $36 million, a reminder that patent cliffs eventually catch up to even the steadiest cash flows. That same risk sits underneath every new deal the company signs, including the one with Zealand.
The rusfertide agreement carries its own strings. Royalty Pharma's 1% royalty stops scaling once global sales pass $1.5 billion, at which point Zealand keeps a 0.25% cut and Royalty Pharma only 0.75%, so the largest commercial outcomes get split rather than fully captured. And rusfertide still has not cleared the FDA. The agency's goal date only falls in the third quarter of 2026, meaning the second $50 million payment is committed before regulators finish their review. Layer that onto a balance sheet carrying $9.2 billion in total debt principal against $812 million of cash as of June 30, 2026, and it becomes clear this is a company funding new bets with borrowed as w

Microsoft's next major AI constraint may be measured in turbines rather than processors. On June 22, Microsoft Corporation (NASDAQ:MSFT) entered a 20-year power purchase agreement with Energy Forge One LLC, a wholly owned subsidiary of Chevron Corporation (NYSE:CVX), for a planned West Texas data-center project. The Kilby development targets 2.67 gigawatts of generation, with initial power expected in 2028. Its scale suggests that securing dependable electricity is becoming as strategic to hyperscalers as securing accelerators.
Tupungato / Shutterstock.com
Microsoft Corporation (NASDAQ:MSFT) gets a dedicated path to capacity in a grid-constrained market. Natural gas can provide round-the-clock generation that complements intermittent renewables and supports the reliability AI clusters require. A two-decade contract can also give developers confidence to finance construction. The bull case is simple: Microsoft protects its cloud growth by solving power locally instead of waiting years for transmission expansion.
Chevron Corporation (NYSE:CVX) gains a new outlet for its gas and an opportunity to move downstream into integrated power. If Kilby works, Chevron can replicate a model that converts energy resources and project expertise into long-duration data-center cash flows. Yet the project has not reached a final investment decision. Construction, permitting, fuel costs, emissions rules, and customer requirements can all change the economics before power begins flowing.
Those uncertainties create bear cases for both companies. Microsoft is committing to an energy pathway as AI hardware and efficiency evolve rapidly, and a long contract can become less attractive if power markets change. Chevron and its partners must commit capital years before the **** et is operational while managing construction, fuel-cost and carbon-policy risks. Gas solves the reliability problem, but it may intensify political and regulatory scrutiny around AI's environmental footprint. The critical milestones are final investment approval, permitting, construction costs, and data showing that the first power date remains achievable. Until those arrive, the agreement secures intent rather than operating supply.

#power #data

Elastic N.V. (NYSE:ESTC) delivered a quarter that should have won over Wall Street. An earnings beat, growing enterprise adoption of its AI-powered search and cloud platform, and guidance pointing to continued revenue growth through fiscal 2027.
The AI-fueled beat led shares spiking more than 15% in after-hours trading, but DA Davidson chose to remain Neutral on the stock. On August 28, the firm raised its price target on Elastic NV (NYSE:ESTC) shares to $100 from $80 while maintaining a Neutral rating.
For first quarter of fiscal 2027 ending July 31, 2026, the Search AI Company announced total revenues of $478 million, an increase of 15% year-over-year. Total subscription revenue also rose by the same percentage year-over-year to $449 million. Sales-led subscription revenue was $399 million, an increase of 18% year-over-year.
Sales-led subscription revenue is a reflection of Elastic's progress with its larger customers, a segment management is explicitly focused on to improve for achieving its long-term financial and product milestones. The company also reported adding more than 80 customers with annual contract value above $100,000, bringing the total to over 1,800.
Firm Da Davidson particularly mentioned the company's improving demand for Elastic's Security solution backed by a heightened threat landscape.

#estc

A clean beat-and-raise, record data center strength, and a newly expanded Alphabet Inc. (NASDAQ:GOOGL) Google partnership should have helped Marvell Technology Inc. (NASDAQ: MRVL) win a major boost from Wall Street. Yet, shares fell more than 8% anyway.
On August 28, Oppenheimer raised its price target on the stock to $325 from $300 while maintaining an Outperform rating. His note serves as a bull case that explains why the selloff was wrong, while the market reaction serves as the bear case for why it wasn't.
Several factors led Oppenheimer to raise its price target and reiterate its Outperform rating. For starters, Marvell's revenue rose 37% to $2.7 billion, $39 million above the company's guidance. The firm noted that the company has raised its calendar year 2026 revenue outlook to $12 billion, up from $11.5 billion last quarter. Marvell now anticipates calendar year 2027 revenue of $18 billion, up from its $16.5 billion outlook in May and $15 billion in March.
A majority of this raise is driven by interconnect products, while the rest is driven by custom chip programs. Its Trainium and Maia programs also remain on track, with Maia likely to contribute $700 million in revenue next year. The quarter highlighted strong AI-related demand across the company's data center portfolio, with data center representing 79% of total revenues.
Speaking of the Google-Marvell expanded partnership announced recently, the firm noted how the full vesting of warrants would imply roughly $120 billion in **** ulative Google purchases over an estimated seven years if milestones are met.

#billion #Google #year #oppenheimer